糖原合成酶激酶3β:在进展性慢性病中的关键参与者
Mingzhuo Zhang1, Marc Tatar2, Rujun Gong1
1Division of Nephrology, Department of Medicine, University of Toledo College of Medicine, Toledo, Ohio, U.S.A.
Clinical science (London, England : 1979)
|June 17, 2025
概括
糖原合成酶激酶3β (GSK3β) 在慢性病 (CKD) 的进展中起着关键作用. 在临床前模型中,用抑制剂准GSK3β显示出减少损伤和促进恢复的前景.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 慢性病 (CKD) 是一种具有重大健康和社会影响的渐进性疾病.
- 糖尿病和高血压等潜在疾病往往会加剧CKD.
- 糖原合成酶激酶3β (GSK3β) 是一种参与胰岛素信号的激酶,并与CKD的发病有关.
研究的目的:
- 审查CKD中GSK3β的分子和细胞机制.
- 突出GSK3β作为慢性脏疾病的潜在治疗点.
主要方法:
- 审查关于GSK3β和CKD的现有文献.
- 分析GSK3β在调节细胞命运和信号通路 (Wnt/β-catenin,NF-κB,Nrf2,PI3K/Akt) 中的作用.
- 检查GSK3β在纤维化和氧化应激等病态变化的参与.
主要成果:
- GSK3β的失调和过活性与损伤有关,包括细胞损伤,中扩张和纤维化.
- 在细胞中持续的GSK3β过活性促进了氧化应激和益纤维细胞信号传递,加速了CKD的进展.
- 临床前研究表明,GSK3β抑制剂减少损伤,减轻纤维化,并有助于恢复.
结论:
- 在CKD的发病和进展中,GSK3β是关键的调解者.
- 向GSK3β是治疗慢性脏疾病的有希望的治疗策略.
相关概念视频
Chronic Kidney Disease I: Introduction
78
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
78
Chronic Kidney Disease III: Interprofessional Care
87
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
87
Chronic Kidney Disease II: Clinical Manifestations
107
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
107
Acute Kidney Injury II: Pathophysiology
101
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
101
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Acute Kidney Injury III: Clinical Manifestations
105
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
105


